← All trials
NCT04894435
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Mar 31, 2023
- First posted
- May 20, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 1200
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Canadian Immunization Research NetworkLead sponsor
- Harvard UniversityCollaborator
- University of OttawaCollaborator
- University of TorontoCollaborator
- Dalhousie UniversityOverall official - principal investigator
- Laval UniversityCollaborator
- University of British ColumbiaCollaborator
- Canadian Center for VaccinologyCollaborator
- Interior Health, CanadaCollaborator
- Government of OntarioCollaborator
- Children's Hospital Research Institute of ManitobaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.